Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05018728 · ClinicalTrials.gov registry record · Phase 2
The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT05018728 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 22 participants.
The verdict
NCT05018728, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
Voxelotor is a new drug for adolescents and adults with sickle cell disease that improves hemoglobin levels and reduces the incidence of worsening anemia. However, it is unclear whether this increase in hemoglobin is associated with a reduction in cerebral metabolic stress. This study will measure the effects of voxelotor on cerebral hemodynamics.
Interventions
- DRUG Voxelotor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2024-10-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05018728
The ClinicalTrials.gov registry entry for NCT05018728 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Voxelotor is the first listed.
NCT05018728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05018728 about?
NCT05018728 is a clinical study titled "The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia". Voxelotor is a new drug for adolescents and adults with sickle cell disease that improves hemoglobin levels and reduces the incidence of worsening anemia. However, it is unclear whether this increase in hemoglobin is associated with a reduction in cerebral metabolic stress. This study will measure t...
What is the current status of trial NCT05018728?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2022-03-28. Estimated completion is 2024-10-22.
What interventions are being tested in trial NCT05018728?
The interventions under investigation include: Voxelotor (DRUG).
Who is sponsoring clinical trial NCT05018728?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.